News & Updates

Co-treatment with methotrexate (MTX) appears to enhance response rates to pegloticase among patients with uncontrolled gout, according to a study.

Treatment with osmotic-release oral system methylphenidate falls short of reducing symptoms of attention-deficit hyperactivity disorder (ADHD) in young adult prisoners, as shown in a study.

In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.

In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.

The endothelin-B receptor agonist sovateltide appears to improve neurological outcomes in patients with acute cerebral ischaemic stroke (ACIS), according to a phase III trial presented at WSC 2022.

Prasugrel appears to better protect against the risk of ischaemic events in patients with acute coronary syndrome (ACS) and prior myocardial infarction (MI) as compared with ticagrelor, without a trade-off in bleeding, a study has found.

Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.

In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.